Search results
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting. Emend is used in patients aged from 6 months to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer).
- ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - European Medicines Agency
EMEND is given for 3 days as part of a regimen that includes...
- Emend, INN-Aprepitant - European Medicines Agency
The indication applied for EMEND by the Applicant is...
- ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS - European Medicines Agency
EMEND is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose is 125 mg orally once daily one hour before start of chemotherapy on Day 1 and 80 mg orally once daily on Days 2 and 3 in the morning.
The indication applied for EMEND by the Applicant is “prevention of acute and delayed nausea and vomiting associated with initial and repeated courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin, in combination with other antiemetic agents”.
Zapobieganie nudnościom i wymiotom związanym z przeciwnowotworową chemioterapią o wysokim i umiarkowanym ryzyku wymiotów u dorosłych i młodzieży w wieku od 12 lat. EMEND 125 mg/80 mg stosuje się w leczeniu skojarzonym (patrz punkt 4.2).
EMEND (aprepitant, MK-0869) is a substance P (NK1 receptor) antagonist, which in combination with other antiemetic agents, is indicated for prevention of acute and delayed nausea and vomiting in adults.
Article summary. Strengths and limitations of this study. This is the first study using a performance-based method to assess the readability of these documents—determining whether people can find and understand the information they need.
22 kwi 2024 · Start of scientific evaluation of your MAA: Day 0 to Day 120. List of questions and outstanding issues: Day 121 to Day 180. Final CHMP opinion on your MAA. When the European Commission adopts the CHMP opinion.
